Scilex Pharmaceuticals
在场
Scilex Pharmaceuticals 的所有者是 Sorrento Therapeutics.
Sorrento Therapeutics 是一家在股票代码 SRNE (US) 下上市的公司。
高管
药店
Sorrento Therapeutics 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Scilex Pharmaceuticals 的最新新闻稿
- News & Events – Scilex Holding
- News & Events - Scilex Holding
- News - Scilex Holding
- Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
- Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
- Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
- Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
- Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
- Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
- Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
- View more press releases Close
通过电子邮件
